Skip to main content
Premium Trial:

Request an Annual Quote

New Quest Vantage Cancer Panels

Quest Diagnostics expanded its Vantage cancer test menu with three new services: the MYvantage 34-gene Hereditary Comprehensive Cancer Panel, which includes 34 high risk, moderate risk, and emerging risk genes associated with a broad spectrum of hereditary cancers; the Glvantage Hereditary Colorectal Cancer Test, which includes 13 genes predominantly associated with colon and gastric cancers; and the Qvantage Hereditary Women's Health Cancer Test, which includes 14 genes predominantly associated with breast, colon, uterine, and ovarian cancers. Each tests only include genes that meet certain criteria, such as two-fold increased cancer risk, association with a disease syndrome for which cancer may occur, and guideline support for genetic counseling, the company said.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.